MedTrace Logo

A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

NCT00092027 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 454

Last updated 2024-08-14

No results posted yet for this study

Summary

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

MK0217, alendronate sodium/Duration of Treatment: 6 months

DRUG

Comparator: placebo / Duration of Treatment: 6 months

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-19
Primary Completion
2004-03-15
Completion
2004-03-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092027 on ClinicalTrials.gov